公开(公告)号：US20230295684A1

公开(公告)日：2023-09-21

申请号：US18147360

申请日：2022-12-28

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran

IPC: C12Q1/44 ,  G01N33/68 ,  A61B5/00

CPC classification number: C12Q1/44 ,  A61B5/4064 ,  G01N33/68 ,  G01N2800/40

Abstract: Disclosed herein are methods and systems of determining whether a subject’s levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in a sample collected from the subject. The methods comprise determining whether the levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in the sample, and communicating the determination on or from an instrument. The methods may be used to aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild, moderate, severe, or moderate to severe traumatic brain injury (TBI).

公开(公告)号：US20210389334A1

公开(公告)日：2021-12-16

申请号：US17316257

申请日：2021-05-10

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino

IPC: G01N33/68

Abstract: Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20210356477A1

公开(公告)日：2021-11-18

申请号：US17316267

申请日：2021-05-10

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul A. Datwyler ,  Raj Chandran

IPC: G01N33/68

Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20250020666A1

公开(公告)日：2025-01-16

申请号：US18804253

申请日：2024-08-14

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul A. Datwyler ,  Raj Chandran

IPC: G01N33/68

Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US11994523B2

公开(公告)日：2024-05-28

申请号：US17224685

申请日：2021-04-07

Applicant: Abbott Laboratories ,  Cedars-Sinai Medical Center

Inventor： Jennifer Van Eyk ,  Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Vidya Venkatraman ,  Shenyan Zhang

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2560/00 ,  G01N2800/28 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/60

Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.

公开(公告)号：US11022617B2

公开(公告)日：2021-06-01

申请号：US16213898

申请日：2018-12-07

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul A. Datwyler ,  Raj Chandran

IPC: G01N33/68

Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20190383832A1

公开(公告)日：2019-12-19

申请号：US16233895

申请日：2018-12-27

Applicant: Abbott Laboratories ,  Cedars-Sinai Medical Center

Inventor： Jennifer Van Eyk ,  Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Vidya Venkatraman ,  Shenyan Zhang

IPC: G01N33/68

Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.

公开(公告)号：US20190219598A1

公开(公告)日：2019-07-18

申请号：US16203373

申请日：2018-11-28

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N33/6893 ,  G01N2800/28 ,  G01N2800/2871 ,  G01N2800/60

Abstract: Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US12092647B2

公开(公告)日：2024-09-17

申请号：US17099668

申请日：2020-11-16

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Justin Rogers ,  Jaime Marino ,  Raj Chandran ,  Tianming Zhang ,  Saul Datwyler

IPC: G01N33/68 ,  A61B5/00 ,  A61B5/055 ,  A61B6/03 ,  A61B6/50

CPC classification number: G01N33/6893 ,  A61B5/0042 ,  A61B5/055 ,  A61B6/03 ,  G01N33/6896 ,  A61B6/032 ,  A61B6/501 ,  G01N2333/914 ,  G01N2333/918 ,  G01N2800/28 ,  G01N2800/40 ,  G01N2800/60

Abstract: Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MRI) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20230258661A1

公开(公告)日：2023-08-17

申请号：US18147420

申请日：2022-12-28

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Hongwei Zhang

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/60 ,  G01N2333/916 ,  G01N2333/47 ,  C12Y301/02015

Abstract: Disclosed herein are methods and systems of determining whether a subject's levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in a sample collected from the subject. The methods comprise determining whether the levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in the sample, and communicating the determination on or from an instrument. The methods may be used to aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild, moderate, severe, or moderate to severe traumatic brain injury (TBI).